Down-regulation of Bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia

Gynecologic Oncology

Volumn 73, Issue 1, 1999, Pages 126-136

  Amezcua, Charles A ^a   Zheng, Wenxin ^a,b   Muderspach, Laila I ^a   Felix, Juan C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; DRUG EFFICACY; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; TISSUE SECTION; TREATMENT OUTCOME;

EID: 0032893186     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5336     Document Type: Article

References (44)

1. Kurman RJ, Kaminski PF, Norris HJ: The behavior of endometrial hyperplasia: a long term study of "untreated" hyperplasia in 170 patients. Cancer 56:403-412, 1985
2. Eichner E, Abellera F, Abellera M: Endometrial hyperplasia treated by progestins. Obstet Gynecol 38:739-742, 1971
3. Gal D, Edman CD, Vellios F, Forney P: Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 146:316-321, 1983
4. Wentz WB: Progestin therapy in endometrial hyperplasia. Gynecol Oncol 2:362-367, 1974
5. Ferenczy A, Gelfand M: The biological significance of cytological atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160:126-131, 1989
6. 2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy? Acta Obstet Gynecol Scand 59:155-159, 1980
7. Ehrlich CE, Young PCM, Cleary RE: Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol 141:539-546, 1981
8. Martin PM, Rolland PH, Gammerre M, Serment H, Toga M: Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy. Int J Cancer 23:321-329, 1979
9. Metzger DA, Lessey BA, Soper JT, McCarty KS, Haney AF: Hormone-resistant endometriosis following total abdominal hysterectomy and bilateral salpingo-oophorectomy: correlation with histology and steroid receptor content. Obstet Gynecol 78:946-950, 1991
10. Murphy LC, Dotzlaw H, Johnson Wong MS, Miller T, Murphy LJ: Mechanisms involved in the evolution of progestin resistance in human breast cancer cells. Cancer Res 51:2051-2057, 1991
11. Satyaswaroop PG, Clarke CL, Zaino RJ, Mortel R: Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following down regulation of tumor progesterone receptor. Cancer Lett 62:107-114, 1992
12. Deligdisch L: Effects of hormone therapy on the endometrium. Mod Pathol 6:94-106, 1993
13. Casper RF: Regulation of estrogen/progesterone receptors in the endome-trium. Int J Fertil 41:16-21, 1996
14. Masuzawa H, Badokhon NH, Nakayama K, Konishi I, Nikaido T, Fujii S: Failure of down-regulation of estrogen receptors and progesterone recep-tors after medroxyprogesterone acetate administration for endometrial hyperplasias. Cancer 74:2321-2328, 1994
15. Janne O, Kauppila A, Kontula K, Syrjala P, Vihko R: Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium: the relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration. Int J Cancer 24:545-554, 1979
16. Chiarugi V, Ruggiero M: Role of three cancer master genes p53, bcl-2 and c-myc on the apoptotic process. Tumori 82:205-209, 1996
17. Hockenbery DM, Nuncy G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
18. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80:879-886, 1992
19. Gompel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y, Poitout P: Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 144:1195-1202, 1994
20. Otsuki Y, Misaki O, Sugimoto O, Ito Y, Tsujimoto Y, Akao Y: Cyclic bcl-2 expression in human uterine endometrium during menstrual cycle. Lancet 344:28-29, 1994
21. Chan WK, Mole MM, Levinson DA, Ball RY, Lu Q, Patel K, Hanby AM: Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol 177:241-246, 1995
22. Chhieng DC, Ross JS, Ambros RA: Bcl-2 expression and the development of endometrial carcinoma. Mod Pathol 9:402-406, 1996
23. Henderson GS, Brown KA, Perkins SL, Abbott TM, Clayton F: Bcl-2 is down-regulated in atypical hyperplasia and adenocarcinoma. Mod Pathol 9:430-438, 1996
24. Niemann TH, Trgovac TL, McGaughy VR, Vaccarello L: Bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 63:318-322, 1996
25. Sabourin JC, Martin A, Baruch J, True JB, Gompel A, Poitout P: Bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59:1-6, 1994
26. Saegusa M, Okayasu I: Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas. J Pathol 182:429-436, 1997
27. Kandouz M, Siromachkova M, Jacob D, Marquet BC, Therwath A, Gompel A: Antagonism between estradiol and progestin on bcl-2 expression in breast-cancer cells. Int J Cancer 68:120-125, 1996
28. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA: p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 61:167-174, 1996
29. Zheng W, Feng Y, Gandhi M, Siu S, Hom E, Caputo T, Lauchlan SC: Persistent expression of bcl-2 onco-protein in endometrial carcinoma correlates with hormone receptor positivity. Int J Gynecol Cancer 6:235-240, 1996
30. Taskin M, Lallas TA, Barber HRK, Shevchuk MM: Bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 10:728-734, 1997
31. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R: Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 15:202-208
32. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54:3253-3259, 1994
33. Elliott MJ, Stribinskiene L, Lock RB: Expression of bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin. Cancer Chemother Pharmacol 41: 457-463, 1998
34. Reed JC: Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9:451-473, 1995
35. Randall TC, Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90:434-440, 1997
36. Koh EAT, Illingworth PJ, Duncan WC, Critchley HOD: Immunolocalization of bcl-2 protein in human endometrium in the menstrual cycle and simulated early pregnancy. Hum Reprod 10:1557-1562, 1995
37. Kokawa K, Shokone T, Nakano R: Apoptosis in the human uterine endometrium during the menstrual cycle. J Clin Endocrinol Metab 81: 4144-4147, 1996
38. Tao X, Tilly KI, Maravei DV, Shifren JL, Krajewski S, Reed JC, Tilly JL, Isaacson KB: Differential expression of members of the bcl-2 gene family in proliferative and secretory human endometrium: glandular epithelial cell apoptosis is associated with increased expression of bax. J Clin Endocrinol Metab 82:2738-2746, 1997
39. Bu S, Yin D, Ren X, Jiang L, Wu Z, Gao Q, Pei G: Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79:1944-1950, 1997
40. Benito A, Grillot D, Nunez G, Fernandez-Luna JL: Regulation and function of bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am J Pathol 146:481-490, 1995
41. Krajewski S, Chatten J, Hanada M, Reed JC: Immunohistochemical analysis of the oncoprotein in human neuroblastomas: comparison with tumor cell differentiation and N-myc protein. Lab Invest 71:42-54, 1995
42. Harada H, Mitsuyasu T, Seta Y, Maruoka Y, Toyoshima K, Yasumoto S: Overexpression of bcl-2 protein inhibits terminal differentiation of oral keratinocytes in vitro. J Oral Pathol Med 27:11-17, 1998
43. Sermadiras S, Dumas M, Joly-Berville R, Bonte F, Meybeck A, Ratinaud MH: Expression of bcl-2 and bax in cultured normal human keratinocytes and melanocytes: relationship to differentiation and melanogenesis. Br J Dermatol 137:883-889, 1997
44. Miranda MC, Mazur MT: Endometrial squamous metaplasia: an unusual response to progestin therapy of hyperplasia. Arch Pathology Lab Med 119:458-460, 1995